SINOPHARM : Announcements and Notices - Announcement Principal Financial Data of Sinopharm (cncm Ltd) for the Nine Months Ended 30 September 2017

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

(A joint stock limited company incorporated in the People's Republic of China with limited liability and carrying on business in Hong Kong as 國控股份有限公司)

(Stock Code: 01099) ANNOUNCEMENT PRINCIPAL FINANCIAL DATA OF SINOPHARM (CNCM LTD) FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2017

Reference is made to the overseas regulatory announcement dated 25 October 2017 (the "Announcement") and issued by Sinopharm Group Co. Ltd. (the "Company") in relation to the summary of the third quarterly report for the nine months ended 30 September 2017 of China National Medicines Corporation Ltd. ("SINOPHARM (CNCM LTD)"), a subsidiary of the Company and whose A shares are listed on the Shanghai Stock Exchange (stock code: 600511).

The board of directors of the Company would like to draw the attention of its shareholders and the public investors to the following principal unaudited financial data of SINOPHARM (CNCM LTD) for the nine months ended 30 September 2017 as set out in the Announcement.

PRINCIPAL FINANCIAL DATA OF SINOPHARM (CNCM LTD)

Unit: Yuan Currency: RMB

As at the end of the reporting period	As at the end of last year		Increase/ decrease at the end of the reporting period as compared to the end of last year (%)
	Before adjustment	After adjustment
Total assets	19,327,318,598.43	16,665,541,979.54	7,401,463,433.29	15.97
Net assets attributable to shareholders of the listed	7,890,645,391.32	5,849,499,679.02	3,521,877,910.90	34.89
From the beginning of the year to the end of the reporting period (January to September)	From the beginning of last year to the end of the reporting period of last year (January to September)		Increase/ decrease as compared to the corresponding period of last year (%)
	Before adjustment	After adjustment
Net cash flows from operating	-577,088,439.66	402,586,235.20	282,592,869.38	-243.35
From the beginning of the year to the end of the reporting period (January to September)	From the beginning of last year to the end of the reporting period of last year (January to September)		Increase/ decrease as compared to the corresponding period of last year (%)
	Before adjustment	After adjustment
Operating Revenue	27,067,656,576.44	25,605,800,012.50	9,918,361,069.75	5.71
Net profit attributable to shareholders of the listed company	835,759,749.06	765,771,452.12	435,241,665.68	9.14
Net profit attributable to shareholders of the listed company net of non-recurring gain or loss	736,918,251.50	429,571,215.44	429,571,215.44	71.55
Weighted average return on net assets (%)	12.31%	14.49%	13.53%	Decreased by 2.18 percentage points
Basic earnings per share (RMB/Share)	1.1512	1.1046	0.9090	4.22
Diluted earnings per share (RMB/Share)	1.1512	1.1046	0.9090	4.22

Note: The above financial indicators are calculated based on the rule related to the "consolidation/merger of enterprises under the common control during the reporting period" under Rules No. 9, namely, Preparation Rules for Information Disclosure by Companies Offering Securities to the Public - Calculation and Disclosure of Return on Equity and Earnings per Share.

This announcement is made pursuant to Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) and Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

By order of the Board of

Sinopharm Group Co. Ltd.

Li Zhiming

Chairman

Shanghai, the PRC 25 October 2017

As at the date of this announcement, the executive director of the Company is Mr. Li Zhiming; the non-executive directors of the Company are Mr. Chen Qi Yu, Mr. She Lulin, Mr. Wang Qunbin, Mr. Ma Ping, Mr. Deng Jindong, Mr. Li Dongjiu, Mr. Lian Wanyong and Mr. Wen Deyong; and the independent non-executive directors of the Company are Ms. Li Ling, Mr. Yu Tze Shan Hailson, Mr. Tan Wee Seng, Mr. Liu Zhengdong and Mr. Zhuo Fumin.

* The Company is registered as a non-Hong Kong company under the Hong Kong Companies Ordinance under its Chinese name and the English name "Sinopharm Group Co. Ltd.".